Submit a case
Home - About VASCERN - Structure and Governance - Working Groups - Rare Disease Working Groups - Hereditary Haemorrhagic Telangiectasia (HHT-WG) - Clinical Decision Support Tools - Clinical Outcome Measures
Hereditary Haemorrhagic Telangiectasia (HHT-WG)
Introduction Disease Covered
Experts & Centers
Experts Centers
Clinical Decision Support Tools
Patient Pathways Do’s and Don’ts Clinical Practice Guidelines (CPGs) adopted Clinical Expert Consensus Statements Written Clinical Outcome Measures
Registry
Research
Clinical Trials/Observational Studies Research Publications
Training and Education
E-Learning Pills of Knowledge Webinars
Based on Evidence European (BEE) Meeting
First Edition | 25th May, 2023

Clinical Outcome Measures

Outcome Measures were developed and implemented by the Hereditary Haemorrhagic Telangiectasia Working Group (HHT-WG) to maximise the number of patients receiving good care. This Clinical Position Statement is based on the 5 Outcome Measures selected by members of the VASCERN HHT-WG.

Result (1)
European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)
March 13 2023

Shovlin CL, Buscarini E, Kjeldsen AD, Mager HJ, Sabba C, Droege F, Geisthoff U, Ugolini S, Dupuis-Girod S. Haematologica. 2019 Feb;104(2):e85-e86. doi: 10.3324/haematol.2018.209791.

Skip to content